Wilms Tumor Protein (WT33 or WT1) - Pipeline Review, H2 2018
According to the recently published report 'Wilms Tumor Protein - Pipeline Review, H2 2018'; Wilms Tumor Protein (WT33 or WT1) pipeline Target constitutes close to 14 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes.
Wilms Tumor Protein (WT33 or WT1) - Wilms tumor protein is a protein that is encoded by the WT1 gene. It plays an important role in cellular development and cell survival. It plays an essential role for development of the urogenital system. It has a tumor suppressor as well as an oncogenic role in tumor formation. It regulates the expression of numerous target genes, including EPO.
The report 'Wilms Tumor Protein - Pipeline Review, H2 2018' outlays comprehensive information on the Wilms Tumor Protein (WT33 or WT1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Wilms Tumor Protein (WT33 or WT1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Preclinical and Discovery stages are 4, 2 and 1 respectively. Similarly, the universities portfolio in Phase II, Phase I and Preclinical stages comprises 3, 3 and 1 molecules, respectively. Report covers products from therapy areas Oncology which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Glioblastoma Multiforme (GBM), Myelodysplastic Syndrome, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Malignant Glioma, Ovarian Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Leukemias, Pancreatic Cancer, Soft Tissue Sarcoma, Solid Tumor, Adrenal Gland Cancer, Essential Thrombocythemia, Fallopian Tube Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Head And Neck Carcinoma, Hematological Tumor, High-Grade Glioma, Lung Cancer, Lymphoma, Malignant Mesothelioma, Malignant Pleural Mesothelioma, Melanoma, Merkel Cell Carcinoma, Metastatic Transitional (Urothelial) Tract Cancer, Multiple Myeloma (Kahler Disease), Neuroblastoma, Non-Small Cell Lung Cancer, Ocular Melanoma, Pediatric Diffuse Intrinsic Pontine Glioma, Peritoneal Cancer, Polycythemia Vera, Renal Cell Carcinoma, Salivary Gland Cancer, Sarcomas, Small Intestine Cancer, Testicular Cancer, Thrombocytosis, Thymic Carcinoma, Thymoma (Thymic Epithelial Tumor) and Transitional Cell Carcinoma (Urothelial Cell Carcinoma).
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook